Literature DB >> 9864259

Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception.

Y F Su1, R W McNutt, K J Chang.   

Abstract

Evidence suggests both opioid mu and delta receptors may participate in the regulation of respiration at different central nervous system sites. In the past, the overlapping receptor specificity of various opioid drugs has made it difficult to dissect the receptor subtype-specific activities involved in respiratory regulation. The new family of delta receptor selective agents such as cyclic[D-Pen2, 5]enkephalin, deltorphins, (+)-4-((alpha-R)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide, naltrindole and H-Tyr-Tic(psi)[CH2NH]Phe-Phe-OH have now made it feasible to more clearly define the role of delta receptors in respiratory control. In a series of experiments we observed that systemic infusion of rats with the highly mu receptor-specific opioid alfentanil induced antinociception and hypercapnia, and both of these effects were antagonized by the mu antagonist D-Phe-Cys-Tyr-Orn-Thr-Pen-Thr-NH2. However, peripheral administration of the delta receptor antagonist naltrindole reverses the hypercapnia but not the antinociceptive activity of alfentanil. This differential effect of naltrindole on antinociception and hypercapnia could also be produced with the delta agonist (+)-4-((alpha-R)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide. In addition, intracerebroventricular delivery of a number of peptide delta ligands cyclic[D-Pen2,5]enkephalin, deltorpnin II and H-Tyr-Tic(psi)[CH2NH]Phe-Phe-OH also produced the same differential reversal of hypercapnia without affecting antinociception. Thus, both the traditional delta agonists and antagonists are able to reverse the alfentanil-induced hypercapnia without affecting antinociception. The reversal of alfentanil-induced hypercapnia by these delta ligands was antagonized by a novel synthetic delta antagonist cis-4-(alpha-(4-((Z)-2-butenyl)-3, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide. We propose that in this experimental respiration model, the delta antagonists naltrindole and H-Tyr-Tic(psi)[CH2NH]Phe-Phe-OH behave like delta agonists with low but sufficient intrinsic activities to reverse alfentanil-induced hypercapnia in rats. The results suggest that a function of the delta receptor is to modulate or counteract the respiratory depression induced by the mu receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9864259

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

Review 1.  Protecting motor networks during perinatal ischemia: the case for delta-opioid receptors.

Authors:  Stephen M Johnson; Sara M F Turner
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

Review 2.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

3.  Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.

Authors:  Sean Henry; Jessica P Anand; Jack J Twarozynski; Ashley C Brinkel; Irina D Pogozheva; Bryan F Sears; Emily M Jutkiewicz; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2020-02-10       Impact factor: 7.446

4.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

5.  The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.

Authors:  Shou-Pu Yi; Qing-Hong Kong; Yu-Lei Li; Chen-Ling Pan; Jie Yu; Ben-Qiang Cui; Ying-Fei Wang; Guan-Lin Wang; Pei-Lan Zhou; Li-Li Wang; Ze-Hui Gong; Rui-Bin Su; Yue-Hai Shen; Gang Yu; Kwen-Jen Chang
Journal:  Acta Pharmacol Sin       Date:  2017-05-15       Impact factor: 6.150

6.  Delta/mu opioid receptor interactions in operant conditioning assays of pain-depressed responding and drug-induced rate suppression: assessment of therapeutic index in male Sprague Dawley rats.

Authors:  Katherine Cone; Janell Lanpher; Abigail Kinens; Philomena Richard; Sarah Couture; Rebecca Brackin; Emily Payne; Kylee Harrington; Kenner C Rice; Glenn W Stevenson
Journal:  Psychopharmacology (Berl)       Date:  2018-03-23       Impact factor: 4.530

Review 7.  Panic, suffocation false alarms, separation anxiety and endogenous opioids.

Authors:  Maurice Preter; Donald F Klein
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-09       Impact factor: 5.067

8.  Role of central and peripheral opiate receptors in the effects of fentanyl on analgesia, ventilation and arterial blood-gas chemistry in conscious rats.

Authors:  Fraser Henderson; Walter J May; Ryan B Gruber; Joseph F Discala; Veljko Puskovic; Alex P Young; Santhosh M Baby; Stephen J Lewis
Journal:  Respir Physiol Neurobiol       Date:  2013-11-24       Impact factor: 1.931

9.  Excitatory and inhibitory effects of opioid agonists on respiratory motor output produced by isolated brainstems from adult turtles (Trachemys).

Authors:  Stephen M Johnson; Christina M Moris; Michelle E Bartman; Liana M Wiegel
Journal:  Respir Physiol Neurobiol       Date:  2009-10-13       Impact factor: 1.931

10.  Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Authors:  Jason R Healy; Padmavani Bezawada; Jihyun Shim; Jace W Jones; Maureen A Kane; Alexander D MacKerell; Andrew Coop; Rae R Matsumoto
Journal:  ACS Chem Neurosci       Date:  2013-06-11       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.